PRPairwise–which launched its first leafy greens blend edited with CRISPR for improved flavour in North America last year–is starting the next phase of commercialization in June 2024. The company has entered into an exclusive product licensing agreement with Bayer to further develop and sell the products at scale.

With higher nutrition compared to lettuce, the leafy greens are a mixture of multi-use mustard green varieties that Pairwise edited using the company's proprietary Fulcrum Platform. By dialing down the wasabi-like flavour of the raw leaves, the company created a new product for consumers who prefer a less-pungent taste but still want the nutrition of fresh mustard greens.

This licensing deal is part of Bayer's new open innovation approach, launched to leverage opportunities for genome-edited fruits and vegetables. The agreement allows Bayer to further develop and commercialize 10 varieties of Pairwise-edited greens, and to develop and breed new varieties with the technology.

"We're extremely proud to have introduced the first CRISPR food in North America last year, demonstrating our ability to deliver a unique product that people want to buy," said Tom Adams, Pairwise co-founder and CEO. "Bayer is a strong partner for this licensing agreement with considerable market reach that we feel can extend the impact and success of our first consumer product widely into the marketplace."

"This agreement and its focus on gene-edited produce made a substantial contribution to our open innovation approach," said JD Rossouw, head of vegetable research & development at Bayer's Crop Science division. "We are excited by the potential for these products as we bring them forward to create a new category of nutritious and great-tasting leafy greens.” 

Source:  Pairwise May 29, 2024 news release